Abstract
Schizophrenia is a severe mental disorder characterized by disturbances of thought, perception, emotion, and behavior leading to considerable suffering and social deterioration. Widely believed to have multiple etiologies, schizophrenia is a syndrome with much variability in age at onset, symptomatology, course of illness, and response to treatment. Symptom development may be insidious or abrupt, with peak age at onset for males occurring in late adolescence or early adulthood. Females show a broader and later peak age at onset, with a second, smaller rise in new cases in the fourth decade.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Similar content being viewed by others
References
Adler, L., Angrist, B., Peselow, E., Corwin, J., Maslansky, R., & Rotrosen, J. (1986). A controlled assessment of propranolol in the treatment of neuroleptic-induced akathisia. British Journal of Psychiatry, 149, 42–45.
Alford, G. (1986). Behavioral treatment of schizophrenic delusions: A single-case experimental analysis. Behavior Therapy, 17(5), 656–644.
Allen, H., & Bass, C. (1992). Coping tactics and the management of acutely distressed schizophrenic patients. Behavioral Psychotherapy, 20(1), 61–72.
American Psychiatric Association (1987). Diagnostic and statistical manual of mental disorders (3rd ed., rev.). Washington, DC: Author.
Anderson, C. M., Reiss, D. J., & Hogarty, G. E. (1986). Schizophrenia in the family. New York: Guilford.
Baldessarini, R. (1990). Drugs and the treatment of psychiatric disorders. In G. A. Gilman, T. W. Roll, A. S. Nies, & T. Palmer (Eds.), The pharmacological basis of therapeutics (pp. 383–435). New York: Pergamon.
Baldessarini, R. J., Cohen, B. M., & Teicher, M. H. (1988). Significance of neuroleptic dose and plasma level in the pharmacological treatment of psychosis. Archives of General Psychiatry, 45, 79–91.
Becker, R. B. (1988). Depression in schizophrenia. Hospital and Community Psychiatry, 39, 1269–1275.
Beitchman, J. H. (1985). Childhood schizophrenia: A review and comparison with adult-onset schizophrenia. Psychiatric Clinics of North America, 8, 793–814.
Campbell, M., Green, W. H., & Deutch, S. I. (1985). Child and adolescent psychopharmacology. Beverly Hills, California: Sage.
Carpenter, W. T., Jr., Strauss, J. S., & Bartko, J. J. (1974). Use of signs and symptoms for the identification of schizophrenic patients. Schizophrenia Bulletin, 11, 37–49.
Carpenter, W. T., Hanlon, T. E., Heinrichs, D. W., Summerfelt, A. T., Kirkpatrick, B., Levine, J., & Buchanan, R. W. (1990). Continuous vs. targeted medication in schizophrenic outpatients: Outcome results. American Journal of Psychiatry, 147, 1138–1148.
Christison, G. W., Kirch, D. G., & Wyatt, R. J. (1991). When symptoms persist: Choosing among alternative treatments for schizophrenia. Schizophrenia Bulletin, 17, 217–245.
Cole, J. O. (1964). NIMH-Psychopharmacology Service Center Collaborative Study Group. Phenothiazine treatment in acute schizophrenia: Effectiveness. Archives of General Psychiatry, 10, 246–261.
Creese, I., Burt, D. R., & Snyder, S. H. (1975). Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. Science, 192, 481–483.
Crow, T. J., MacMillan, J. F., Johnson, A. L., & Johnstone, E. C. (1986). The Northwick Park study of first episodes of schizophrenia. II. A randomized controlled study of prophylactic neuroleptic treatment. British Journal of Psychiatry, 148, 115–120.
Davis, J. M. (1975). Overview: Maintenance therapy in psychiatry. I. Schizophrenia. American Journal of Psychiatry, 132, 1237–1245.
Deberdt, R., Elens, P., Berghmans, J., Heykants, R., Woestenborghs, F., Reyntjiens, A., & Van Wungaarden, I. (1980). Intramuscular haloperidol decanoate for neuroleptic maintenance therapy. Acta Psychiatrica Scandinavica, 62, 356–565.
Dunham, H. W. (1965). Community and schizophrenia: An epidemiological analysis. Detroit: Wayne State University Press.
Ganguli, R., Rabin, B. S., & Kelly, R. H. (1989). Multiple autoantibodies and autoimmune process in schizophrenic patients: Evidence for an autoimmune pathogenesis. In Hadden, J. W., Masek, K, & Nistico, G. (Eds.), Interaction among CNS, neuroendocrine and immune systems (pp. 365–383). Rome-Milan: Pythagora.
Goff, C. G., & Baldessarini, R. J. (1993). Drug interactions with antipsychotic agents. Journal of Clinical Psychopharmacology, 13(1), 57–67.
Goldstein, M. J., Rodrick, E. H., Evans, J. R., May, P. R. A., & Steinberg, M. R. (1978). Drug and family therapy in the aftercare of acute schizophrenics. Archives of General Psychiatry, 35, 1169–1177.
Herz, M. I., & Melville, C. (1980). Relapse in schizophrenia. American Journal of Psychiatry, 137, 801–805.
Hogarty, G. E., Anderson, C. M., Reiss, D. T., Kornblith, S. T., & Greenwald, D. P. (1986). Family psychoeducation, social skills training, and maintenance chemotherapy in the aftercare of schizophrenia. Archives of General Psychiatry, 43, 633–642.
Hogarty, G. E., McEvoy, J. P., Munetz, M., Dibarry, A. L., Bartone, P., & Cather, R. (1988). Environmental/personal indicators in the course of schizophrenia research group: Dose of fluphenazine, familial expressed emotion, and outcome in schizophrenia. Archives of General Psychiatry, 45, 797–805.
Jann, M. W., Ereshefsky, L, & Saklad, S. R. (1985). Clinical pharmacokinetics of the depot antipsychotics. Clinical Pharmacokinetics, 10, 315–333.
Javitt, D. C., & Zukin, S. R. (1991). Recent advances in the phencyclidine model of schizophrenia. American Journal of Psychiatry, 148, 1301–1308.
Kane, J. M. (1989). The current status of neuroleptic therapy. Journal of Clinical Psychiatry, 50, 322–328.
Kane, J. M., & Lieberman, J. A. (1987). Maintenance pharmacotherapy in schizophrenia. In H. Y. Meltzer (ED), Psychopharmacology: The third generation of progress. New York: Raven.
Kane, J. M., & Selzer, J. (1991). Consideration of “organic” exclusion criteria for schizophrenia. Schizophrenia Bulletin, 17, 69–73.
Kane, J. M., Woerner, M., Weinhold, P., Wegner, J., Kinon, B., & Borenstein, M. (1984). Incidence of tardive dyskinesia: Five-year data from a prospective study. Psychopharmacology Bulletin, 20, 387–389.
Keshavan, M. S., & Keshavan, A. (1992). Drug induced psychotic disorders. In Keshavan, M. S., & Kennedy, J. S. (Eds.), Drug-induced dysfunction in psychiatry (pp. 202–207). New York: Hemisphere.
Kingdon, D. G., & Turkington, D. (1992). The use of cognitive behavioral therapy with a normalizing rationale in schizophrenia: Preliminary report. Journal of Nervous and Mental Disease, 179(4), 207–211.
Leff, J., Kuipers, L., Berkowitz, R., & Sturgeon, D. (1985). A controlled trial of social intervention in the families of schizophrenic patients: Two year follow up. British Journal of Psychiatry, 146, 594–600.
Lieberman, J. A., Kane, J. M., & Johns, C. A. (1989). Clozapine: Guidelines for clinical management. Journal of Clinical Psychiatry, 50, 329–338.
Malm, U. (1982). The influence of group therapy on schizophrenia. Acta Psychiatrica Scandinavica, 297(Suppl.), 1–65.
May, P. R., Tuma, A. H., Yale, C., Potepan, P., & Dixon, W. J. (1976). Schizophrenia—A follow-up study of results of treatment. II: Hospital stay over two to five years. Archives of General Psychiatry, 33, 481–506.
McCracken, J. T. (1987). Lead intoxication psychosis in an adolescent. Journal of the American Academy of Child and Adolescent Psychiatry, 26, 274–276.
McEvoy, J. P., Hogarty, G. E., & Steingard, S. (1991). Optimal dose of neuroleptic in acute schizophrenia. Archives of General Psychiatry, 48, 739–745.
Murray, R. M., O’Callaghan, E., Castle, D. J., & Lewis, S. (1992). A neurodevelopmental approach to the classification of schizophrenia. Schizophrenia Bulletin, 18(2), 319–332.
Nasrallah, H. A. (1986). The differential diagnosis of schizophrenia: Genetic, perinatal, neurological, pharmacological and psychiatric factors. In H. A. Nasrallah & D. R. Weinberger (Eds.), Handbook of schizophrenia (pp. 49–64). New York: Elsevier.
Nayak, R. K., Doose, D. R., & Nair, N. P. V. (1987). The bioavailability and pharmacokinetics of oral and intramuscular haloperidol in schizophrenic patients. Journal of Clinical Psychopharmacology, 27, 144–150.
Profita, J., Carrey, N., & Klein, F. (1989). Sustained, multimodal outpatient group therapy for chronic psychotic patients. Hospital and Community Psychiatry, 40(9), 943–946.
Realmuto, G. M., Erickson, W. D., Yellin, A. M., Hopwood, J. H., & Greenberg, L. M. (1984). Clinical comparison of thiothixene and thioridazine in schizophrenic adolescents. American Journal of Psychiatry, 141, 440–442.
Rifkin, A., Seshagiri, D., Basawaraj, K., Borenstein, M., & Wachpress, W. (1991). Dosage of haloperidol for schizophrenia. Archives of General Psychiatry, 48, 166–170.
Rifkin, A., & Siris, S. (1987). Drug treatment of acute schizophrenia. In H. Y. Meltzer (Ed.), Psychopharmacology: The third generation of progress (pp. 1095–1102). New York: Raven.
Roy, A. (1986). Suicide in schizophrenia. In A. Roy (Ed.), Suicide (pp. 95–112). Baltimore: Williams & Wilkins.
Salzman, C. (1989). Use of benzodiazepines to control disruptive behavior in inpatients. Journal of Clinical Psychiatry, 49(Suppl). 13–15.
Schneider, K. (1959). Clinical psychopathology. New York: Grune & Stratton.
Schooler, N. (1991). Maintenance medication for schizophrenia: Strategies for dose reduction. Schizophrenia Bulletin, 17, 311–324.
Schooler, N., & Hogarty, G. (1987). Medication and psychosocial strategies in the treatment of schizophrenia. In H. Y. Meltzer (Ed.), Psychopharmacology: The third generation of progress (pp. 1111–1120). New York: Raven.
Simpson, G. E., Yadalam, K. G., Levinson, D. F., Stephanos, M. J., Lo, E. S., & Cooper, T. B. (1990). Single-dose pharmacokinetics of fluphenazine after fluphenazine decanoate administration. Journal of Clinical Psychopharmacology, 10(6), 417–421.
Stanton, A. H., Gunderson, J. G., Knapp, P. H., Frank, A. F., Vanicelli, M. L., Schnitzer, R., & Rosenthal, R. (1984). Effects of psychotherapy in schizophrenia. Schizophrenia Bulletin, 10, 520–563.
VanPutten, T. (1974). Why do schizophrenic patients refuse to take their drugs? Archives of General Psychiatry, 31, 67–72.
VanPutten, T., Marder, S., & Mintz, J. (1990). A controlled dose comparison of haloperidol in newly admitted schizophrenic patients. Archives of General Psychiatry, 47, 754–758.
Vaughn, C. E., & Leff, J. P. (1976). The influence of family and social factors on the course of psychiatric illness. British Journal of Psychiatry, 129, 125–137.
Wallace, C. J., & Iiberman, R. P. (1985). Social skills training for patients with schizophrenia: A controlled clinical trial. Psychiatry Research, 15, 239–247.
Werry, J., McClellan, J., & Chard, L. (1991). Childhood and adolescent schizophrenia, bipolar, and schizo-affective disorders: A clinical and outcome study. Journal of the American Academy of Child and Adolescent Psychiatry, 30, 457–465.
Wyatt, R. J. (1991). Neuroleptics and the natural course of schizophrenia. Schizophrenia Bulletin, 17, 325–351.
Yadalam, K. G., & Simpson, G. M. (1988). Changing from oral to depot fluphenazine. Journal of Clinical Psychiatry, 49(9), 346–348.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1994 Springer Science+Business Media New York
About this chapter
Cite this chapter
Anderson, S.A., Vaulx-Smith, P., Keshavan, M.S. (1994). Schizophrenia. In: Hersen, M., Ammerman, R.T. (eds) Handbook of Prescriptive Treatments for Adults. Springer, Boston, MA. https://doi.org/10.1007/978-1-4899-1456-9_4
Download citation
DOI: https://doi.org/10.1007/978-1-4899-1456-9_4
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4899-1458-3
Online ISBN: 978-1-4899-1456-9
eBook Packages: Springer Book Archive